Opinion|Videos|December 30, 2024
Administering Bispecifics in the Community vs Academic Centers
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss understanding the comparative advantages, decision-making factors, infrastructure requirements, and partnership models for administering bispecific antibodies in community vs academic settings, with particular focus on patient care logistics and referral pathways.
Advertisement
Episodes in this series
Video content above is prompted by the following
- What are the benefits of administering bispecific antibodies in the community setting compared with tertiary centers?
- What factors might influence the decision to administer these agents at an academic center instead of in a community setting?
- What kind of infrastructure is needed to administer these agents in the community setting that poses key challenges?
- How are you partnering with academic or community centers to support these patients? What is your internal referral pathway?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Estradiol-Containing MHT May Impact Alzheimer Disease-Related Biomarkers in Postmenopausal Women
2
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
3
CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution
4
MHT Use Can Affect Cognitive Health Depending on Administration Method
5
